Stock listing

NYSE American:RGNT Regentis Biomaterials Ltd. Stock

Home listing (NYSE American) of Regentis Biomaterials Ltd.

Follow Regentis Biomaterials Ltd. into a list and get an email when it puts out news.

Share price · AMEX:RGNT

$0.719 USD -0.121 (-14.4%)

Close on Nov 20, 2026

This year -90.4% · daily closes, Dec 4, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.712 – $0.889 USDNov 20, 2026
Volume
122,345 sharesNov 20, 2026
Market cap
$5.05M USDAt the close on Nov 20, 2026 · price × 7.02M shares outstanding
Traded on an average day
$79,982 USDMedian day 24,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Regentis Biomaterials Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:RGNT · Home$0.719 USD-0.121 (-14.4%)122,345$0.880$0.889$0.712$0.840Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:RGNT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.719-0.121-14.4%$0.880$0.889$0.712122,345
$0.840-0.300-26.3%$0.840$1.080$0.811179,762
$1.140-0.080-6.6%$1.215$1.215$1.1409,157
$1.220+0.030+2.5%$1.230$1.230$1.14013,014
$1.190-0.040-3.3%$1.310$1.310$1.19012,579
$1.230-0.020-1.6%$1.240$1.290$1.22023,600
$1.250-0.020-1.6%$1.270$1.270$1.18025,100
$1.270-0.060-4.5%$1.340$1.340$1.22541,300
$1.330+0.060+4.7%$1.315$1.340$1.190204,800
$1.270+0.080+6.7%$1.180$1.690$1.180220,300
$1.190+0.020+1.7%$1.172$1.220$1.16023,400
$1.170-0.150-11.4%$1.300$1.355$1.17090,300
$1.320-0.050-3.6%$1.370$1.410$1.26418,300
$1.3700.0000.0%$1.360$1.430$1.3408,600
$1.3700.0000.0%$1.360$1.440$1.36015,300
$1.370+0.010+0.7%$1.420$1.420$1.31024,900
$1.360+0.130+10.6%$1.280$1.470$1.26561,800
$1.230-0.060-4.7%$1.260$1.300$1.23017,600
$1.290+0.030+2.4%$1.270$1.415$1.25027,000
$1.260-0.020-1.6%$1.300$1.320$1.26025,200
$1.280-0.120-8.6%$1.420$1.420$1.28018,400
$1.400-0.090-6.0%$1.480$1.480$1.40050,700
$1.490+0.020+1.4%$1.510$1.559$1.48414,200
$1.470-0.010-0.7%$1.530$1.540$1.47013,800
$1.480-0.010-0.7%$1.440$1.600$1.44036,100
$1.490-0.060-3.9%$1.600$1.600$1.46023,500
$1.550+0.040+2.6%$1.550$1.560$1.50014,300
$1.510-0.115-7.1%$1.650$1.650$1.450132,600
$1.625-0.005-0.3%$1.630$1.670$1.59033,400
$1.630+0.030+1.9%$1.620$1.645$1.60036,100
$1.600-0.100-5.9%$1.670$1.740$1.60022,200
$1.700+0.070+4.3%$1.690$1.730$1.650172,800
$1.630-0.020-1.2%$1.640$1.690$1.63017,000
$1.650-0.020-1.2%$1.670$1.740$1.65034,000
$1.670-0.180-9.7%$1.830$1.860$1.660109,500
$1.850+0.020+1.1%$1.850$1.874$1.78029,000
$1.830+0.020+1.1%$1.860$1.880$1.8009,000
$1.810-0.040-2.2%$1.870$1.980$1.81022,200
$1.850-0.040-2.1%$1.920$1.920$1.80058,600
$1.890-0.090-4.5%$1.950$1.970$1.8557,600
$1.980-0.060-2.9%$2.060$2.080$1.90017,200
$2.040-0.060-2.9%$2.080$2.080$2.00025,000
$2.100+0.010+0.5%$2.135$2.150$2.05015,100
$2.090-0.140-6.3%$2.170$2.170$2.09041,200
$2.230+0.420+23.2%$1.850$2.480$1.850440,400
$1.810+0.060+3.4%$1.800$1.890$1.73022,800
$1.750-0.050-2.8%$1.820$1.870$1.75020,607
$1.800-0.010-0.6%$1.810$1.850$1.74027,400
$1.810-0.070-3.7%$1.890$1.890$1.750194,400
$1.880-0.010-0.5%$1.900$1.960$1.87516,600
$1.890-0.070-3.6%$2.020$2.020$1.89016,542
$1.960-0.050-2.5%$2.010$2.010$1.91512,800
$2.010-0.030-1.5%$2.060$2.070$1.98010,500
$2.040+0.070+3.6%$2.000$2.040$1.92055,800
$1.9700.0000.0%$1.940$2.000$1.94015,900
$1.970-0.050-2.5%$2.060$2.060$1.94054,300
$2.020-0.040-1.9%$2.050$2.090$2.02014,500
$2.060+0.020+1.0%$2.040$2.110$2.00538,500
$2.040+0.040+2.0%$2.000$2.140$2.00024,400
$2.000-0.060-2.9%$2.100$2.100$2.00019,636
$2.060-0.010-0.5%$2.120$2.120$2.0608,200
$2.070-0.020-1.0%$2.080$2.155$2.04019,100
$2.090-0.070-3.2%$2.100$2.140$2.00019,800
$2.160+0.060+2.9%$2.150$2.180$1.96025,600
$2.100+0.040+1.9%$2.050$2.170$2.05037,200
$2.060-0.170-7.6%$2.140$2.220$2.06046,000
Ticker
NYSE American:RGNT
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Regentis Biomaterials Ltd. news

Regentis Biomaterials Ltd. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
13 in the last 12 months · 13 in all · newest Nov 9, 2026 · oldest 2025
Decks
4 decks · latest September 2026

Where Regentis Biomaterials Ltd. is listed

ListingExchangeCountryCurrency
NYSE American:RGNT · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:RGNTBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 1.3×: 5th lowest of 11 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$3.90M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.00

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Regentis Biomaterials Ltd. · AMEX:RGNTUS$5.05M−US$3.90Mn/an/an/a0.7×n/a0.0×2.00
NeuroOne Medical Technologies Corporation · NASDAQ:NMTCUS$5.94MUS$3.89Mn/a0.4×n/a1.6×−78.6%0.0×1.07
Neola Medical AB · OMXSTO:NEOLAUS$5.47MUS$5.08Mn/an/an/a0.6×n/a0.0×n/a
ENDRA Life Sciences Inc. · NASDAQ:NDRAUS$5.36MUS$3.85Mn/an/an/a1.0×n/a0.0×1.07
MEKICS Co., Ltd. · KRX:058110US$5.23MUS$2.04M6.6×0.2×1.3×0.2×7.7%0.1×n/a
PT Hetzer Medical Indonesia Tbk · IDX:MEDSUS$5.16MUS$5.45Mn/an/an/a1.8×n/a0.1×n/a
SeaStar Medical Holding Corporation · NASDAQ:ICUUS$4.97MUS$981,429n/a0.5×n/a10.6×−678.2%0.0×1.44
WORK Medical Technology Group LTD · NASDAQ:WOKUS$4.84MUS$8.21Mn/a0.8×n/a0.2×−10.9%0.2×2.76
Kelyniam Global, Inc. · OTC:KLYGUS$4.56MUS$4.84Mn/a1.4×31.9×6.6×−6.0%0.6×1.15
Meihua International Medical Technologies Co., Ltd. · OTC:MHUAFUS$4.53M−US$1.63M0.7×−0.0×−0.2×0.0×11.0%0.1×0.62
Aurora Spine Corp. · TSXV:ASGUS$4.36MUS$6.91Mn/a0.4×45.6×1.5×−7.0%1.0×-0.13
Median of the othersUS$5.07MUS$4.37M3.7×0.4×16.6×1.3×−7.0%0.1×1.07

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.68 · 1 analyst

Team and board

Officers

OfficerRole
Ehud GellerCEO & Chairman
Ori GonCFO & CBO
Liora SklairVP R&D
Orly AmiranVP Quality & Regulatory Affairs
Raz SimonVP Product & Applications
Galit ReskeChief Medical Officer
Nadya LisovoderDirector of Clinical Operations

Board

DirectorRole
Ehud GellerCEO & Chairman
Efraim Cohen AraziDirector
Jeff DykanDirector
Keith ValentineDirector
Pini Ben-ElazarDirector
Susan AlpertDirector

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck23 slidesSeptember 2026
IPO Roadshow (May 2026)IPO roadshow26 slidesMay 29, 2026
IPO Roadshow (October 2025)IPO roadshow25 slidesOct 6, 2025
IPO Roadshow (July 2025)IPO roadshow25 slidesJul 7, 2025

Open Decks

Financings

RaiseDate
Private placement of ordinary shares (or pre-funded warrants) with ordinary warrants
Announced: about US$6.5M · US$3.5 a share · Warrants at US$4.2 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: GelrinC pivotal trial and FDA PMA preparation, Gelrin platform, manufacturing scale-up, European market entry, working capital
Jun 18, 2026
Public offering of ordinary shares
Closed: US$10M raised · US$8 a share · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Development activities including completing its pivotal trial and PMA submission prep for GelrinC, plus debt repayment and deferred compensation
Dec 5, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a share on Dec 3, 2025.

Price
US$8.00 a share
Shares offered
1,250,000 ordinary shares
Offering size
US$10 million
Underwriters' option
Up to 187,500 more shares
Listing
RGNT on NYSE American
Underwriter
ThinkEquity
Shares delivered
On or about Dec 5, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceNov 21, 2024
Filed publiclyMar 11, 2025
Amended 6 timesNewest Oct 24, 2025
Shares registered with an exchangeSep 9, 2025
Final prospectus, with the priceDec 4, 2025

Filings

FilingFiled
424B3 · ProspectusDec 4, 2025
CERT · Exchange's certificate of listingDec 3, 2025
FWP · Free writing prospectusOct 24, 2025
F-1/A · Registration statement, amendedOct 24, 2025
FWP · Free writing prospectusOct 6, 2025
F-1/A · Registration statement, amendedSep 30, 2025
CORRESP · Letter to the SECSep 17, 2025
CORRESP · Letter to the SECSep 17, 2025
CORRESP · Letter to the SECSep 15, 2025
CORRESP · Letter to the SECSep 15, 2025
All 34 filings
FilingFiled
CORRESP · Letter to the SECSep 10, 2025
8-A12B · Registration of shares for listing on an exchangeSep 9, 2025
F-1/A · Registration statement, amendedSep 9, 2025
CORRESP · Letter to the SECSep 8, 2025
CORRESP · Letter to the SECSep 8, 2025
FWP · Free writing prospectusJul 7, 2025
F-1/A · Registration statement, amendedJul 7, 2025
CORRESP · Letter to the SECMay 19, 2025
F-1/A · Registration statement, amendedMay 19, 2025
UPLOAD · Letter from the SECMay 13, 2025
CORRESP · Letter to the SECMay 5, 2025
F-1/A · Registration statement, amendedMay 5, 2025
UPLOAD · Letter from the SECMar 19, 2025
F-1 · Registration statementMar 11, 2025
CORRESP · Letter to the SECMar 10, 2025
UPLOAD · Letter from the SECFeb 19, 2025
DRS/A · Draft registration statement, amendedFeb 12, 2025
DRSLTR · Letter to the SEC with a draftFeb 11, 2025
UPLOAD · Letter from the SECFeb 5, 2025
DRS/A · Draft registration statement, amendedJan 27, 2025
DRSLTR · Letter to the SEC with a draftJan 24, 2025
DRS · Draft registration statementJan 24, 2025
UPLOAD · Letter from the SECDec 18, 2024
DRS · Draft registration statementNov 21, 2024

Open IPO · From the cover of the final prospectus (424B3) filed Dec 4, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Research and development331.0K1.64M806.0K971.0K
Selling, general and administrative8.29M712.0K1.13M436.0K
Operating income-6.97M932.0K-1.93M-1.41M
Interest expense79.0K10.0K173.0K0
Income before tax13.6M-4.80M4.13M-1.45M
Net income-13.6M4.80M-4.13M-1.45M
Earnings per share, basic-24.161.72-24.09-0.29
Earnings per share, diluted-24.161.72-24.09

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents7.38M229.0K345.0K1.24M
Current assets7.62M482.0K360.0K1.72M
Total assets7.62M482.0K360.0K1.72M
Accounts payable266.0K252.0K353.0K206.0K
Current liabilities2.87M6.49M3.14M2.61M
Long-term debt7.41M6.47M
Total liabilities2.87M6.49M46.3M43.8M
Shareholders' equity4.74M-41.1M-45.9M-42.1M
Shares outstanding5.18M162.2K5.18M4.93M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-1.38M-641.0K-1.22M-1.50M
Capital spending0000
Free cash flow-1.38M-641.0K-1.22M-1.50M
Cash from financing8.52M525.0K325.0K0
Change in cash7.15M-116.0K-895.0K-1.50M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 23, 2026Other filingsSEC
POS AM · Amendment to an effective registrationSep 17, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 15, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJul 14, 2026Other filingsSEC
All 94 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 13, 2026Insider tradeSEC
424B3 · ProspectusJul 13, 2026Offer documentSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 9, 2026Current reportSEC
F-1 · Registration statementJul 8, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 2, 2026Current reportSEC
DJun 25, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 18, 2026Current reportSEC
6-K · Report of a foreign issuerJun 15, 2026Current reportSEC
RW · Request to withdraw a registrationJun 15, 2026Other filingsSEC
F-1/A · Registration statement, amendedJun 9, 2026Offer documentSEC
6-K · Report of a foreign issuerJun 8, 2026Current reportSEC
6-K/A · Report of a foreign issuer, amendedJun 4, 2026Current reportSEC
FWP · Free writing prospectusMay 29, 2026Offer documentSEC
6-K · Report of a foreign issuerMay 28, 2026Current reportSEC
F-1 · Registration statementMay 1, 2026Offer documentSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
20-F/A · Annual report, amendedFeb 27, 2026Annual reportSEC
20-F · Annual reportFeb 24, 2026Annual reportSEC
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 5, 2026Current reportSEC
6-K · Report of a foreign issuerJan 29, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
DRS · Draft registration statementJan 7, 2026Offer documentSEC
6-K · Report of a foreign issuerJan 6, 2026Current reportSEC
6-K · Report of a foreign issuerJan 6, 2026Current reportSEC
6-K · Report of a foreign issuerDec 18, 2025Current reportSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
424B3 · ProspectusDec 4, 2025Offer documentSEC
CERT · Exchange's certificate of listingDec 3, 2025Other filingsSEC
FWP · Free writing prospectusOct 24, 2025Offer documentSEC
F-1/A · Registration statement, amendedOct 24, 2025Offer documentSEC
FWP · Free writing prospectusOct 6, 2025Offer documentSEC
F-1/A · Registration statement, amendedSep 29, 2025Offer documentSEC
CORRESP · Letter to the SECSep 17, 2025Other filingsSEC
CORRESP · Letter to the SECSep 17, 2025Other filingsSEC
CORRESP · Letter to the SECSep 15, 2025Other filingsSEC
CORRESP · Letter to the SECSep 15, 2025Other filingsSEC
CORRESP · Letter to the SECSep 10, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 9, 2025Other filingsSEC
F-1/A · Registration statement, amendedSep 8, 2025Offer documentSEC
CORRESP · Letter to the SECSep 8, 2025Other filingsSEC
CORRESP · Letter to the SECSep 8, 2025Other filingsSEC
FWP · Free writing prospectusJul 7, 2025Offer documentSEC
F-1/A · Registration statement, amendedJul 7, 2025Offer documentSEC
CORRESP · Letter to the SECMay 19, 2025Other filingsSEC
F-1/A · Registration statement, amendedMay 19, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 13, 2025Other filingsSEC
CORRESP · Letter to the SECMay 5, 2025Other filingsSEC
F-1/A · Registration statement, amendedMay 5, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 19, 2025Other filingsSEC
F-1 · Registration statementMar 11, 2025Offer documentSEC
CORRESP · Letter to the SECMar 10, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 19, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftFeb 11, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedFeb 11, 2025Offer documentSEC
UPLOAD · Letter from the SECFeb 5, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedJan 24, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftJan 24, 2025Other filingsSEC
DRS · Draft registration statementJan 24, 2025Offer documentSEC
UPLOAD · Letter from the SECDec 18, 2024Other filingsSEC
DRS · Draft registration statementNov 21, 2024Offer documentSEC
RW · Request to withdraw a registrationNov 21, 2024Other filingsSEC
F-1/A · Registration statement, amendedDec 19, 2022Offer documentSEC
F-1/A · Registration statement, amendedDec 7, 2022Offer documentSEC
F-1 · Registration statementNov 4, 2022Offer documentSEC
DRS/A · Draft registration statement, amendedSep 23, 2022Offer documentSEC
DRS/A · Draft registration statement, amendedAug 22, 2022Offer documentSEC
DRS/A · Draft registration statement, amendedJul 22, 2022Offer documentSEC
DRS · Draft registration statementMar 28, 2022Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Regentis Biomaterials Ltd.’s releases · as of Jun 18, 2026

Common shares
7,023,921
Fully diluted
7,023,921

Fully diluted

LineShares
Common shares7,023,921

Share count over time

CountShares
Nov 22, 20267,023,921

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Keith Valentine
Other companies: Alphatec Holdings, Inc. (Director · Since at least Jul 29, 2024); Orthofix Medical Inc. (President & CEO, Director · Jan 5, 2023 – Feb 28, 2023 · Past); SI-BONE, Inc. (Director · Oct 16, 2018 – Jun 9, 2023 · Past); SeaSpine Holdings Corp (Chief Executive Officer, Director · Jun 11, 2015 – Jan 5, 2023 · Past); NuVasive Inc (COO · Jan 3, 2006 – Jan 27, 2015 · Past)
Director · Since at least Mar 18, 2026
Arie Gordashnikov
Other companies: Core AI Holdings, Inc. (Chief Financial Officer · Since at least Jul 1, 2026)
Chief Accounting Officer · Since at least Mar 18, 2026
Efraim Cohen Arazi
Other companies: PRF Technologies Ltd. (Interim CEO, Director · Since at least Mar 18, 2026)
Director · Since at least Mar 18, 2026
Ehud Geller
Other companies: PRF Technologies Ltd. (Executive Chairman & Interim CEO · Since at least Mar 18, 2026)
CEO & Chairman · Since at least Mar 18, 2026
Jeff Dykan
Other companies: Lifeward Ltd. (Director · Dec 31, 2015 – Sep 13, 2023 · Past)
Director · Since at least Mar 18, 2026
Ori Gon
Other companies: Lifeward Ltd. (Chief Financial Officer · Feb 22, 2018 – Jun 30, 2021 · Past)
CFO & CBO · Since at least Mar 18, 2026
Susan Alpert
Other companies: Medtronic plc. (SrVP Chief Regulatory · Jun 8, 2006 – Aug 3, 2009 · Past)
Director · Since at least Mar 18, 2026
Galit ReskeChief Medical Officer · Since at least Mar 18, 2026
Liora SklairVP R&D · Since at least Nov 5, 2026
Nadya LisovoderDirector of Clinical Operations · Since at least Nov 5, 2026
All 13 people
PersonSeat
Orly AmiranVP Quality & Regulatory Affairs · Since at least Nov 5, 2026
Pini Ben-ElazarDirector · Since at least Mar 18, 2026
Raz SimonVP Product & Applications · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Regentis Biomaterials Ltd.